Hospira, Alliance for Health Reform Bring FDA, Industry Experts Together to Discuss the Future of Biosimilars in the US
Hospira joined forces with the Alliance for Health Reform and Amgen to bring the FDA and industry leaders together to discuss the future of biosimilars in the US.
With the US Congress focused intently on the discovery, development and delivery pipeline for innovative drugs and devices — and in the wake of the first-ever US approval of a biosimilar medication — key biosimilars policy and regulatory questions are being actively debated, with important implications for industry, patients and the healthcare system.
Moderated by Ed Howard, executive vice president of the Alliance for Health Reform, expert panelists discussed the US and global markets for reference biologics and biosimilars, outlined current policy and regulatory issues, and described implications for the future of the US biosimilar industry.
Panelists included
• Sally Howard, J.D., deputy commissioner for policy, planning, and legislation, FDA
• Sumant Ramachandra, M.D., Ph.D., senior vice president and chief scientific officer, Hospira
• Amanda Bartelme, director, Avalere
• Geoff Eich, executive director, external affairs for Amgen Biosimilars.
"There is an unmet need that requires governments to develop strategies to help increase the understanding of biosimilars, to support successful market formation and to unlock value to help fund healthcare for their citizens," said Sumant Ramachandra, M.D., Ph.D., senior vice president and chief scientific officer, Hospira. "In order to advance a positive market formation and uptake of biosimilars in the United States, public stakeholder understanding and support of biosimilars needs to be a priority."
Hospira is currently marketing biosimilars in Australia, Canada and Europe, where the company has seen biosimilars decrease the costs of biologics by 20–30%. This has allowed these global healthcare systems to reduce their healthcare spending, while at the same time increasing patient access to these important biologic medicines.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance